Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 15 Jul 2024 Planned End Date changed from 27 Oct 2025 to 12 Dec 2024.
- 15 Jul 2024 Planned primary completion date changed from 27 Oct 2025 to 12 Dec 2024.
- 22 May 2023 Planned End Date changed from 31 Jul 2026 to 27 Oct 2025.